ArticleEndocrine2025
An in-depth exploration of the catecholamine and dyslipidemia relationship in pheochromocytoma and paraganglioma patients: a large Chinese cohort study.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThe aim is to investigate the relationship between catecholamine levels and dyslipidemia in pheochromocytoma and paraganglioma (PPGL) patients.
methodsClinical data from 500 PPGL patients were retrospectively analyzed, including clinical demographics, genetic mutations, tumor size, preoperative catecholamine levels, and lipid profiles. Comparison of lipid levels before and after surgery were also conducted.
resultsA total of 500 patients were included: 238 males (47.6%) and 262 females (52.4%), with an average age at diagnosis of 46.5 ± 15.4 years. The prevalence of dyslipidemia among PPGL patients was 59.2%. In different catecholamine secretion types, norepinephrine (NE) secreting type group had significantly higher total cholesterol levels (4.82 [4.21, 5.38] vs. 4.43 [3.78, 4.92] mmol/L, p < 0.0167) compared to the non-secreting type group. However, there were no significant differences in triglycerides, high-density lipoprotein, and low-density lipoprotein among different secretion types. This study showed the first detailed analysis of the distribution of elevated total cholesterol in different age groups and BMI categories. Patients with overweight had the highest rate of elevated total cholesterol (48.5%). Additionally, within different age brackets, individuals aged 51-60 years displayed the highest rate of abnormal total cholesterol levels. Comparison of preoperative and postoperative biochemical outcomes in 69 patients with PPGLs showed that surgical resection effectively reduced catecholamine levels and improved total cholesterol levels.
conclusionsThe incidence of dyslipidemia is high among patients with PPGL, and there exists strong link between lipid metabolism and catecholamine secretion, thus highlighting the importance of closely monitoring lipid levels in patients with PPGL.
Indexed as
Identifiers
40360875What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.